Gossamer Bio, Inc. stockholders approved several proposals at a special meeting on July 14, 2026. Key approvals include an amendment to the 2019 Incentive Award Plan and a charter amendment to increase authorized common stock from 700,000,000 to 4,000,000,000 shares. This increase supports future issuances related to $72.0 million in New Convertible Notes and the exercise of 135,789,000 purchase warrants. Additionally, stockholders approved a series of charter amendments to implement a reverse stock split and a proportionate reduction in authorized shares. Gossamer Bio, Inc. is a biotechnology company.

Gossamer Bio, Inc. announced the initial conversion rate for its 7.50% Convertible Senior Secured First Lien Notes due 2030. The conversion rate is set at 5,347.5936 shares of common stock per $1,000 principal amount, resulting in a conversion price of approximately $0.19 per share. Additionally, the initial exercise price for its purchase warrants to buy common stock is $0.34 per share. Gossamer Bio, Inc. is a biopharmaceutical company.

Gossamer Bio, Inc. announced the final tender results for its exchange offer to exchange 5.00% Convertible Senior Notes due 2027 for up to $72.0 million in aggregate principal amount of new 7.50% Convertible Senior Secured First Lien Notes due 2030, common stock, and warrants. The company is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutic solutions for inflammatory and inflammatory-related diseases.

Gossamer Bio completed an early settlement of its exchange offer, cancelling $181,052,000 in aggregate principal of 5.00% Convertible Senior Notes due 2027. In exchange, the company issued $65,174,000 of new 7.50% Convertible Senior Secured First Lien Notes due 2030, 254,150,441 shares of common stock, 33,402,727 prefunded warrants, and 135,789,000 purchase warrants. Approximately $18,948,000 of the original convertible notes remain outstanding.

Gossamer Bio, Inc. reported the results of its annual meeting of stockholders. Shareholders re-elected Faheem Hasnain and Russell Cox as Class II directors, ratified Ernst & Young LLP as the independent accounting firm, and approved executive officer compensation on an advisory basis.